Positive Results for Hernexeos in NSCLC Treatment
A phase 3 trial is underway for Hernexeos (zongertinib) as a first-line treatment for non-small cell lung cancer (NSCLC) with HER2 mutations.
Positive results were reported at the European Society for Medical Oncology (ESMO) Congress meeting in Berlin, showing promise for Hernexeos in treating NSCLC with HER2 mutations.
The FDA granted accelerated approval to Hernexeos in August 2025 for previously treated patients, but the recent results are from a phase 1 study of untreated patients.
A phase 3 randomized controlled trial, Beamion LUNG-2, has started enrollment, according to Sanjay Popat, M.B.B.S., Ph.D.
HER2 mutations are found in a relatively small percentage of NSCLC tumors, between 2% and 4%.
No direct quote available in the text.
Author's summary: Hernexeos shows promise as a first-line treatment for NSCLC with HER2 mutations.
More News
- Manchester United’s stance on Kobbie Mainoo leaving Old Trafford in January revealed
- Borrower Monitoring, AI Processing, DPA, Verification Tools; Events and Training; Robots Will do What?
- TBA, Appraisal, Reverse Mortgage Tools; STRATMOR on AI and Competition; Can the CFPB be Willed Away?
- Brewers Go Out With a Whimper in NLCS
- EU Updates Age Verification Standards for Minors
- Fabrizio Romano has terrible news for Tottenham midfielder